Oral Dissolving Strip vs Buccal Patch: Comfort Compared

Oral Dissolving Strip vs Buccal Patch: Comfort Compared

Watch: Oral Dissolving Strip vs Buccal Patch — video

By Jack Zheng, MS Pharmacy — Founder of MIHIYO Labs

Summary

Long-wear mucoadhesive buccal systems, such as the FDA-approved miconazole buccal tablet Oravig, are designed to remain attached for many hours; Oravig showed an average adhesion time of about 15 hours. An oral dissolving strip (ODS) is a different category of oral-mucosal product: MIHIYO Labs formulates its ODS to dissolve within roughly a minute. That duration difference plausibly affects comfort — gum or mouth irritation has been documented with long-wear mucoadhesive buccal systems such as the testosterone buccal system Striant, with about 4 percent of patients discontinuing therapy — though no direct head-to-head ODS-versus-buccal-patch comfort study was identified for this article. Energy-Focus is formulated around that shorter-contact approach.

Is an oral dissolving strip more comfortable to wear than a buccal patch?

For everyday repeat-use dosing, an oral dissolving strip is likely to feel less intrusive than a buccal patch, because it remains in the mouth for far less time — though no direct head-to-head ODS-versus-buccal-patch comfort study was identified among the sources reviewed for this article. The difference is a design-duration choice, not an accident of manufacturing. A buccal patch is engineered to stay fixed against the cheek or gum for hours, releasing its dose slowly while it stays in place. An oral dissolving strip is engineered to do close to the opposite: hydrate, release, and disappear in well under two minutes. In my formulation work on transmucosal films, that duration target is close to the entire design decision. A film designed for prolonged mucosal residence begins to share more functional characteristics with a long-wear mucoadhesive system, whereas a rapidly dissolving ODS is optimized around a much shorter contact window — and a patch engineered to dissolve in a minute cannot hold its mucoadhesive bond long enough to do the job a true buccal patch is built for.

The two formats also feel different in the mouth in ways a spec sheet does not capture. A patch is a discrete object a wearer can locate with the tongue for as long as it stays in place, and that persistent physical presence is part of what a buccal patch is designed to do — hold position despite routine mouth movements such as talking and swallowing. A rapidly dissolving ODS is designed to be noticed only for as long as it takes to dissolve, then to leave no dosage form behind to track.

How do buccal patches and oral dissolving strips actually stay on — or leave — the mucosa?

Buccal patches are specifically designed around sustained mucoadhesion: the process by which certain water-swellable polymers form temporary bonds with the mucin layer coating the oral mucosa, the moist tissue lining the cheek, gum, and under-tongue surfaces1. That bond forms in stages — the polymer hydrates, its chains interpenetrate with mucin, and the two layers form a temporary mechanical and chemical bond2. Some oral dissolving films also use mucoadhesive polymers, but rapidly dissolving ODS products do not necessarily depend on prolonged mucoadhesion for their function. A buccal patch, by contrast, is formulated to maximize and prolong the bond: thicker matrices, backing layers that direct release only toward the mucosa (a "unidirectional" design that also blocks saliva washout), and polymer blends chosen for adhesion strength over disintegration speed3.

Buccal and sublingual films can be designed to promote transmucosal absorption, whereas rapidly dissolving oral films may deliver some or most of their dose after swallowing, depending on the active ingredient and formulation. Swallowed drugs face hepatic first-pass metabolism, the process by which the liver breaks down a portion of an absorbed compound before it reaches general circulation, and formulations aiming for meaningful transmucosal uptake are built specifically to reduce that loss. Salbutamol, for example, has oral bioavailability of roughly 40 percent because of extensive first-pass loss, which is part of why researchers have formulated it into mucoadhesive buccal patches as an alternative route3. MIHIYO's own formulation target for its ODS — a 30-to-60-second dissolve — is a design choice specific to our products, not a claim that every oral dissolving strip on the market is engineered to the same window.

The unidirectional backing layer used on many buccal patches is worth defining, because it is a structural feature a rapidly dissolving ODS such as MIHIYO's does not require. That backing is an inert, non-adhesive film laminated onto the outward-facing side of the patch, so the drug-containing layer can only release toward the mucosa and not into saliva3. It is an effective way to reduce swallowed loss and unwanted taste. The backing layer adds a persistent structural component that remains in the mouth during wear — a feature a rapidly dissolving ODS does not require, because it is not trying to hold a fixed position long enough for a backing layer to matter.

How a long-wear buccal system and MIHIYO's oral dissolving strip interact with the oral mucosa A long-wear buccal system is designed to sustain a mucoadhesive bond against the cheek or gum for hours behind a unidirectional backing layer, while MIHIYO's oral dissolving strip is designed to hydrate and dissolve within about 30 to 60 seconds. Long-wear buccal system Oral dissolving strip (ODS) Placed against cheek or gum Mucoadhesive polymer hydrates Placed on the tongue Film-forming polymer hydrates Bond sustained by design Backing layer blocks saliva contact for hours Hydrates and dissolves ~30-60 sec, MIHIYO's target Hours of fixed contact Film fully dissolved

What do the wear-time, absorption, and comfort data actually show?

The figures below come from different drugs, formulations, and patient populations. They illustrate mechanism and real-world tolerability signals, not a head-to-head trial between a buccal patch and an ODS for the same active ingredient — a gap flagged explicitly in each row rather than left implied.

Dimension Buccal patch / long-wear buccal system Oral dissolving strip (ODS) Source
Design contact time Hours — a miconazole 50 mg buccal tablet showed average adhesion of 15 hours in healthy volunteers Seconds to about a minute — MIHIYO's formulation target is a 30-to-60-second dissolve window Oravig prescribing information4
Absorption while attached Can support local, largely non-systemic action (miconazole) or meaningful systemic absorption (fentanyl buccal film: 71% absolute bioavailability, with about 51% absorbed across the buccal mucosa) Fixed contact with the mucosa is limited to the film's hydration and dissolution period; after the film dissolves, released drug may still remain in saliva, undergo further mucosal uptake, or be swallowed for gastrointestinal absorption Vasisht et al., 20105; Oravig label4
Wear-related tolerability Gum or mouth irritation has been documented with long-wear mucoadhesive buccal systems such as the testosterone buccal system Striant; about 4% of patients discontinued treatment specifically for gum- or mouth-related adverse events in the product's clinical trial data No comparable long-wear irritation signal identified among the sources reviewed for this article — a single 30-to-60-second application does not maintain fixed mucosal contact for hours Striant prescribing information6
Local procedural use A 2025 randomized trial found a lidocaine-dexmedetomidine buccal patch significantly reduced dental-injection pain compared with a drug-free patch, showing that buccal patches can serve a localized therapeutic role Not designed for local pre-procedure anesthesia; MIHIYO's strips are built for a fast supplement dose without requiring a pill or capsule to be swallowed, not a sustained local drug effect Panahandeh et al., 20257
Design contact time and gum-related discontinuation reported for long-wear buccal systems compared with MIHIYO's oral dissolving strip A long-wear buccal tablet such as Oravig shows average mucosal adhesion of about 15 hours, while MIHIYO's oral dissolving strip targets a 30-to-60-second dissolve; separately, about 4 percent of users of the testosterone buccal system Striant discontinued treatment for gum- or mouth-related adverse events per its prescribing information. Design contact time (illustrative, not to scale) Oral dissolving strip (MIHIYO's target) ~30-60 sec Long-wear buccal tablet (Oravig, human data) ~15 hours Box widths are for label clarity only, not proportional to duration -- a roughly 900-fold difference cannot be shown to scale. Gum- or mouth-related discontinuation, testosterone buccal system (Striant) ~4% discontinued for gum- or mouth-related adverse events Source: Striant (testosterone buccal system) prescribing information. Not measured for buccal patches or oral dissolving strips.

On design contact time: Oravig's 15-hour average adhesion is a specific, measured number from an FDA-reviewed formulation, not a generic "patches last hours" estimate — and it illustrates why patch engineers optimize for bond strength while ODS formulators optimize for the opposite4. On absorption: the fentanyl buccal film data show that about 51% of the administered dose was absorbed through the buccal mucosa, while the remainder was swallowed; only part of that swallowed fraction ultimately contributed to systemic exposure, after gastrointestinal absorption and hepatic first-pass metabolism took their own share5 — a reminder that "buccal" does not mean "fully bypasses the gut" for either dosage form. On tolerability: the roughly 4% discontinuation figure for the testosterone buccal system Striant is documented safety data from that product's own clinical trials, not a generalized claim about all buccal patches or films, and no comparable long-wear ODS irritation data exists because an ODS is not designed to be worn that long in the first place6. On procedural use: the 2025 dental-pain trial is a useful reminder that "buccal patch" is a broad category — some are built for systemic drug delivery, others for localized comfort applications an ODS was never intended to replace7; this article does not repeat the trial's specific pain scores, since its published abstract and in-text results tables report different numbers for the same comparison.

What this means for MIHIYO's Energy-Focus strip

MIHIYO Labs does not sell a buccal patch, so this is a comparison of mechanisms and design philosophies, not our product against a specific competitor's. Caffeine is already rapidly and efficiently absorbed after conventional oral ingestion — a classic human crossover study found oral caffeine reaches peak plasma concentration in about 30 minutes, with absorption essentially complete9. Alternative oral-mucosal formulations may alter early absorption depending on formulation and delivery method, but MIHIYO's 30-to-60-second dissolve target for Energy-Focus should be understood as a formulation strategy, not a claim that this has been demonstrated in a clinical trial on our product. The oral mucosa is one possible route for that strategy; a multi-hour patch format was not the direction we chose, because it would trade user comfort for a duration advantage this formulation does not require. No published study has tested a caffeine buccal patch directly against a caffeine ODS, so this remains a design rationale grounded in mucoadhesion and permeability research, not a benchmarked comparison.

Where this comparison falls short

A long-wear mucoadhesive buccal system's extended contact window is a genuine advantage for actives that benefit from sustained local or systemic delivery — products such as Oravig and Striant are specifically designed around hours-long mucosal residence, rather than the seconds-long contact window of a rapidly dissolving film. An oral dissolving strip cannot replicate that: its drug-loading capacity is limited, and actives that require extended mucosal exposure to reach an effective dose are generally not good candidates for a fast-dissolving film8. Conversely, none of the tolerability data cited here were generated on a MIHIYO product, and none of the comfort research directly compares patch-wearer discomfort to strip use for the same drug — this article compares dosage-form mechanisms and published safety signals, not a controlled head-to-head trial. Saliva volume, placement, and individual mucosal thickness still affect how any oral-mucosal product performs in practice, for both patches and films. A patch's removal step also deserves an honest mention: unlike a strip that fully dissolves, a patch that has not been engineered for complete disintegration must eventually be removed and discarded, which is a minor but real usability difference an ODS does not have.

The bottom line

In the oral dissolving strip vs buccal patch comparison, the two formats are designed around very different contact durations, and that difference is likely to influence how intrusive they feel during use. Long-wear mucoadhesive buccal systems can support sustained or local drug delivery, but some systems have documented local tolerability issues; an oral dissolving strip instead trades prolonged fixation for a brief, rapidly dissolving dose. Caffeine is already efficiently absorbed after conventional oral ingestion, so there is no established pharmacologic requirement for hours of buccal fixation. I therefore designed Energy-Focus around speed and convenience rather than sustained fixation — a decision the pharmacology, not marketing, drove.

References

  1. Jacob S, Nair AB, Boddu SHS, Gorain B, Sreeharsha N, Shah J. An Updated Overview of the Emerging Role of Patch and Film-Based Buccal Delivery Systems. Pharmaceutics. 2021;13(8):1206. DOI: 10.3390/pharmaceutics13081206. PMID: 34452167.
  2. Reddy CM, Chaitanya KSC, Rao MY. A review on bioadhesive buccal drug delivery systems: current status of formulation and evaluation methods. DARU Journal of Pharmaceutical Sciences. 2011;19(6):385-403. PMID: 23008684.
  3. Prasanth VV, Puratchikody A, Mathew ST, Ashok KB. Development and characterization of Eudragit based mucoadhesive buccal patches of salbutamol sulfate. Saudi Pharmaceutical Journal. 2011;19(4):207-214. DOI: 10.1016/j.jsps.2011.07.003. PMID: 23960761.
  4. ORAVIG (miconazole) buccal tablets — full prescribing information. Revised June 2021. DailyMed.
  5. Vasisht N, Gever LN, Tagarro I, Finn AL. Single-Dose Pharmacokinetics of Fentanyl Buccal Soluble Film. Pain Medicine. 2010;11(7):1017-1023. DOI: 10.1111/j.1526-4637.2010.00875.x. PMID: 20492573.
  6. STRIANT (testosterone buccal system) — full prescribing information. DailyMed, U.S. National Library of Medicine. DailyMed label.
  7. Panahandeh E, Ghassami E, Etemadi Sh M, Seyedyousefi S, Varshosaz J. Does Unidirectional Buccal Patches Loaded With Lidocaine and Dexmedetomidine Ameliorate Injection Pain in Dental Procedures? A Double-Blinded Randomized Controlled Trial. Journal of Clinical Pharmacy and Therapeutics. 2025;2025:9930530. DOI: 10.1155/jcpt/9930530.
  8. Jacob S, Boddu SHS, Bhandare R, Ahmad SS, Nair AB. Orodispersible Films: Current Innovations and Emerging Trends. Pharmaceutics. 2023;15(12):2753. DOI: 10.3390/pharmaceutics15122753. PMID: 38140094.
  9. Blanchard J, Sawers SJA. The absolute bioavailability of caffeine in man. European Journal of Clinical Pharmacology. 1983;24(1):93-98. DOI: 10.1007/BF00613933. PMID: 6832208.

By — Founder of MIHIYO Labs. Focused on the R&D of high-bioavailability, fast-absorption oral dissolving strips.

0 comments

Leave a comment

Please note, comments need to be approved before they are published.